Shamburg News · 8-K filed Nov 10, 2026, 8:10 AM EST

Cingulate CEO Provides Update on CTx-1301 NDA Resubmission Timeline in Media Interview

CING · Cingulate Inc.

  • Reg FD disclosure
  • Other event
  • Other
  • Materiality: medium

On November 10, 2026, Cingulate Inc. announced that Chairman and CEO Shane J. Schaffer discussed efforts to address the FDA's Complete Response Letter for the CTx-1301 new drug application, progress to date, and the anticipated NDA resubmission timeline in an interview on Innovators with Jane King. The company's Item 8.01 disclosure states it expects to resubmit the NDA between December 2026 and January 2027, with a possible commercial launch in the third quarter of 2027 subject to FDA approval. The filing notes no assurance regarding resubmission timing, FDA classification, or approval.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001493152-26-050870.

Written from the filing by Shamburg Markets. Figures are as reported by the company.